Investors hoping that tax cuts and aggressive government spending plans will add another leg to the bull market likely are going to be disappointed, Morgan Stanley argues in an analysis that contends the end of big returns is near.
Our Top Pick for more speculative investors is a biopharmaceutical company that discovers, develops, and commercializes oral antivirals in areas of unmet medical needs in the United States, explains Bill Mathews, editor of The Cheap Investor.
The lead product candidate from Chimerix (CMRX) is brincidofovir (CMX001), a nucleotide analog.
The drug is in Phase III clinical trials....More>>>
Lands’ End (NASDAQ:LE) CMO Gill Brown Hong bought 1,525 shares of the company’s stock in a transaction on Friday, April 13th. The shares were bought at an average price of $22.20 per share, with a total value of $33,855.00. Following the completion of the transaction, the chief marke
Enbridge Energy, Limited Partnership (NYSE:EEP) had its target price lowered by Barclays from $16.00 to $11.00 in a research report sent to investors on Tuesday morning, Marketbeat reports. The brokerage currently has an equal weight rating on the pipeline company’s stock.